Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

References

• Lurie N, Keusch GT, Dzau VJ. Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development. The Lancet. 2021;397(10280):1229–1236.
   PubMed Web of Science ®Google Scholar
• Lythgoe MP, Middleton P. Comparison of COVID-19 vaccine approvals at the US food and drug administration, european medicines agency, and health Canada. JAMA Netw Open. 2021;4(6):e2114531.
   PubMed Web of Science ®Google Scholar
• Simon D, Tascilar K, Fagni F, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021;80(10):1312–1316.
   PubMed Web of Science ®Google Scholar
• Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628–639.
   PubMed Web of Science ®Google Scholar
• Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol. 2021;85(5):1274–1284.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. The Lancet Rheumatology. 2021;3(9):e627–e37.
   PubMedGoogle Scholar
• Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci. 2004;9:411–420.
   PubMed Web of Science ®Google Scholar
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.
   PubMed Web of Science ®Google Scholar
• Baker JF, George MD. Prevention of infection in the perioperative setting in patients with rheumatic disease treated with immunosuppression. Curr Rheumatol Rep. 2019;21(5):17.
   PubMed Web of Science ®Google Scholar
• Kovarik J. From immunosuppression to immunomodulation: current principles and future strategies. Pathobiology. 2013;80(6):275–281.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.
   PubMed Web of Science ®Google Scholar
• Kurtzman D, Vleugels RA, Callen J, et al. Immunosuppressive and immunomodulatory drugs. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatrick’s dermatology. 9th ed. New York (NY): mcGraw-Hill Education; 2019.
   Google Scholar
• Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724–e36.
   PubMedGoogle Scholar
• Reich K, Warren RB, Coates LC, et al. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161–1173.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Schäkel K, Hong CH, et al. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. J Dermatolog Treat. 2021;33(3):1718–1726.
   PubMed Web of Science ®Google Scholar
• Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174–1185.
   PubMed Web of Science ®Google Scholar
• Klavdianou K, Lazarini A, Grivas A, et al. Real life efficacy and safety of secukinumab in Biologic-Experienced patients with psoriatic arthritis. Front Med (Lausanne). 2020;7:288.
   PubMed Web of Science ®Google Scholar
• Williams T, Wadeley A, Bond D, et al. Real-world experience of secukinumab treatment for ankylosing spondylitis at the royal national hospital for rheumatic diseases, bath. Clin Rheumatol. 2020;39(5):1501–1504.
   PubMed Web of Science ®Google Scholar
• Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–1338.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 2022;4(1):e42–e52.
   PubMedGoogle Scholar
• Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80(10):1306–1311.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Eviatar T, Peleg H, et al. Humoral immunogenicity to a second and third doses of COVID-19 vaccine BNT162b2 in patients with spondyloarthritis receiving secukinumab: a prospective study [POS1244] Annals of the Rheumatic Diseases. 2022;81(Suppl 1):956.
   Google Scholar
• Smetanova J, Strizova Z, Sediva A, et al. Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab. Lancet Rheumatol. 2022;4(3):e163–e6.
   PubMedGoogle Scholar
• Damiani G, Allocco F, Malagoli P, Young Dermatologists Italian Network. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–1108.
   PubMed Web of Science ®Google Scholar
• Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021;80(10):1317–1321.
   PubMed Web of Science ®Google Scholar
• Al-Janabi A, Littlewood Z, Griffiths CEM, et al. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. Br J Dermatol. 2021;185(3):646–648.
   PubMed Web of Science ®Google Scholar
• Benucci M, Damiani A, Infantino M, et al. Vaccination for SARS-CoV-2 in patients with psoriatic arthritis: can therapy affect the immunological response? Front Med. 2022;9:811829.
   Web of Science ®Google Scholar
• Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2022;21(1):102927.
   PubMed Web of Science ®Google Scholar
• Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-Centre, open-label study. Lancet Rheumatol. 2021;3(11):e789–e97.
   PubMedGoogle Scholar
• Paces J, Strizova Z, Smrz D, et al. COVID-19 and the immune system. Physiol Res. 2020;69(3):379–388.
   PubMed Web of Science ®Google Scholar
• Frey S, Chiang TP-Y, Connolly CM, et al. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. Lancet Rheumatol. 2022;4(4):e241–e3.
   PubMedGoogle Scholar
• Frey S, Connolly CM, Chiang TP-Y, et al. Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination. Lancet Rheumatol. 2021;3(11):e753–e4.
   PubMedGoogle Scholar
• Shrotri M, Navaratnam AMD, Nguyen V, Virus Watch Collaborative, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385–387.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cantero A, Aassi M, Alarcon I. Understanding real-world experiences and the impact of COVID-19 vaccination on the associated use of biologics in patients with psoriasis and psoriatic arthritis through social media monitoring. Presented at the 30th European Academy of Dermatology and Venereology (EADV) Congress, Virtual Meeting 2021.
   Google Scholar
• National Psoriasis Foundation. COVID-19 task force guidance statements. 2021. https://www.psoriasis.org/covid-19-task-force-guidance-statements/
   Google Scholar
• Gelfand JM, Armstrong AW, Bell S, et al. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 1. J Am Acad Dermatol. 2020;83(6):1704–1716.
   PubMed Web of Science ®Google Scholar
• Waldman RA, Grant-Kels JM. Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: a critical appraisal of recent food and drug administration and advisory committee on immunization practices recommendations. J Am Acad Dermatol. 2021;85(5):1113–1116.
   PubMed Web of Science ®Google Scholar